Intervacc AB is a Swedish biotech company in the frontline of vaccine development. The research is focused on the new generation of recombinant vaccines within animal health. The company has after many years of research almost finalized the development of a safe and efficacious vaccine Strangvac® against the highly contagious disease strangles in horses caused by Streptococcus equi. Research has also been initiated aiming at developing recombinant vaccines against Streptococcus zooepidemicus, another most important infectious agent in horses. A recombinant vaccine against Staphylococcus aureus causing bovine mastitis is also in the pipeline.